Antaros Tracer is a sister company to Antaros Medical, formed to ensure an expedited and focused development of new Positron Emission Tomography (PET) tracers to be used as important biomarkers in drug development studies. Current disease area focus is fibrotic disease and immune-system activation in immuno-oncology, inflammatory disease, and immunology.
Location: United States, New York, Sweden
Employees: 51-200
Founded date: 2014
Investors 1
| Date | Name | Website |
| - | BioVenture... | azbioventu... |
Mentions in press and media 3
| Date | Title | Description |
| 19.05.2026 | Lauxera Capital Partners: €520 Million Fund Raised For European Healthtech Expansion | Lauxera Capital Partners announced the successful close of its Lauxera Growth II fund at €520 million, surpassing its €500 million hard cap and nearly doubling the size of the firm’s debut fund. The oversubscribed fund was finalized less th... |
| 25.09.2024 | Cracking Cirrhosis: Complexity of Chronic Liver Disease and Insights for Drug Development, Upcoming Webinar Hosted by Xtalks | www.antarosmedical.com In this free webinar, gain insights into how chronic liver disease is complex and why there is still more to be learned about the pathophysiological processes driving disease progression. Attendees will learn how the ... |
| 16.04.2024 | The Incretin Impact: A New Era in Metabolic Disease and Obesity Drug Development, Upcoming Webinar Hosted by Xtalks | www.antarosmedical.com In this free webinar, learn about incretins and their effects throughout the body. Attendees will learn why the future of incretin drug development will likely expand with different combinations, formulations and dise... |